Torrent Pharmaceuticals announced that the United States Food & Drug Administration (USFDA) conducted a routine GMP inspection at its formulation manufacturing facility in Pithampur, Madhya Pradesh, between September 16 and September 20, 2024. The inspection concluded with the issuance of a Form FDA 483, highlighting one observation which is procedural in nature.
The company has assured that it will respond to the USFDA within the prescribed timeframe and collaborate closely with the agency to resolve the observation as quickly as possible.
Shares of Torrent Pharma were trading 2.18% higher at ₹3,425.05 on NSE following the announcement.